$1.580
+0.052 (+3.27%)At close
LPCN News
LPCN Events
Lipocine Secures Health Canada Approval for TLANDO via Verity
Lipocine announced that, through Lipocine's licensing partner Verity Pharmaceuticals, Health Canada has approved TLANDO capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone. Verity Pharma holds exclusive commercial rights to TLANDO in North America and is planning for launch and commercialization in the Canadian market by the end of 2026. More than 700,000 prescriptions are written annually in Canada for TRT, and approximately 50% of this patient population is covered through private insurance.
Lipocine Initiates Phase 3 Study for LPCN 1154
Lipocine announced the initiation of BLOOM, a Phase 3 study evaluating LPCN 1154 for PPD. First participant dosing is expected in early Q4 2026. LPCN 1154 is being developed as a 48-hour, at-home treatment, targeting the need for rapid symptom relief with a short oral regimen. Lipocine believes this potential profile could address a substantial unmet need in PPD and represents an important commercial opportunity, subject to successful development and approval. Based on its current operating plan, Lipocine believes its existing financial and operational resources are sufficient to execute BLOOM. The company expects average cash use of approximately $1M per month during study execution, inclusive of BLOOM-related expenditures. As of June 30, 2026, Lipocine reported $23.3M in unrestricted cash, cash equivalents and marketable investment securities. These expectations are dependent upon study duration, enrollment, costs and other operating requirements and do not imply that existing resources will fund regulatory approval or commercialization.
Lipocine Reports Q2 Revenue of $2.4M
Reports Q2 revenue $2.4M vs. $123K last year. As of June 30, 2026, Lipocine had $23.3 million of unrestricted cash, cash equivalents, and marketable investment securities, compared to $14.9 million at December 31, 2025.
Lipocine Announces Phase 3 Trial Results for LPCN 1154
Lipocine announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 - oral brexanolone - for the treatment of postpartum depression, or PPD. LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D total score compared to placebo at hour 60 in the full analysis set and the primary was not met. The results showed LPCN 1154 to be well tolerated and demonstrated a favorable safety profile to support outpatient administration without the need for healthcare provider monitoring. No treatment-related severe or serious adverse events were reported; no cases of excessive sedation or loss of consciousness were observed; and no treatment-related discontinuations were reported. The company identified signals that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with PPD. While the company is waiting for feedback from the FDA on such designations, the company plans to preserve capital and engage with stakeholders, including investors, regulators, and advisors, to evaluate all options available to the company going forward. Such options may include, but are not limited to, continued development of LPCN 1154, including the potential submission of a validation study protocol, development of other product candidates, strategic transactions, partnerships, and other opportunities.
Lipocine Completes Final Patient Visit in Phase 3 Trial of LPCN 1154
Lipocine announced that the last patient has completed the final study visit in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The randomized, double-blind, placebo-controlled study enrolled a total of 90 patients with severe PPD, having an average baseline Hamilton depression rating scale of 28.3. LPCN 1154 has shown a positive safety profile, with all reported nervous system adverse events being mild to moderate in severity. Furthermore, there were no instances of drug discontinuation, excessive sedation, loss of consciousness, or drug-related serious adverse events.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.